Olaplex (NASDAQ:OLPX – Get Free Report) and Dermata Therapeutics (NASDAQ:DRMAW – Get Free Report) are both consumer staples companies, but which is the superior stock? We will contrast the two companies based on the strength of their analyst recommendations, earnings, valuation, dividends, risk, profitability and institutional ownership.
Profitability
This table compares Olaplex and Dermata Therapeutics’ net margins, return on equity and return on assets.
| Net Margins | Return on Equity | Return on Assets | |
| Olaplex | -3.53% | 2.23% | 1.31% |
| Dermata Therapeutics | N/A | N/A | N/A |
Analyst Recommendations
This is a summary of recent recommendations and price targets for Olaplex and Dermata Therapeutics, as provided by MarketBeat.
| Sell Ratings | Hold Ratings | Buy Ratings | Strong Buy Ratings | Rating Score | |
| Olaplex | 1 | 5 | 1 | 0 | 2.00 |
| Dermata Therapeutics | 0 | 0 | 0 | 0 | 0.00 |
Earnings and Valuation
This table compares Olaplex and Dermata Therapeutics”s revenue, earnings per share (EPS) and valuation.
| Gross Revenue | Price/Sales Ratio | Net Income | Earnings Per Share | Price/Earnings Ratio | |
| Olaplex | $425.35 million | 3.27 | -$9.25 million | ($0.02) | -103.50 |
| Dermata Therapeutics | N/A | N/A | N/A | N/A | N/A |
Dermata Therapeutics has lower revenue, but higher earnings than Olaplex.
Institutional and Insider Ownership
87.4% of Olaplex shares are owned by institutional investors. 4.8% of Olaplex shares are owned by company insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a stock is poised for long-term growth.
Summary
Olaplex beats Dermata Therapeutics on 8 of the 9 factors compared between the two stocks.
About Olaplex
Olaplex Holdings, Inc. develops, manufactures, and sells hair care products in the United States and internationally. The company offers hair care shampoos and conditioners for use in treatment, maintenance, and protection of hair, as well as oil, moisture mask, and nourishing hair serum. It provides hair care products to professional hair salons, retailers, and everyday consumers. The company distributes its products through professional distributors in salons, directly to retailers for sale in their physical stores, e-commerce sites, and its website, Olaplex.com, as well as third party e-commerce platforms. The company was founded in 2014 and is based in Santa Barbara, California.
About Dermata Therapeutics
Dermata Therapeutics, Inc., a late-stage medical dermatology company, focuses on identifying, developing, and commercializing pharmaceutical product candidates for the treatment of medical and aesthetic skin conditions and diseases. The company's lead product candidate is DMT310, which has completed Phase IIb clinical trial for treatment of moderate-to-severe acne; and Phase Ib proof of concept (POC) trial for Mild-to-Moderate Psoriasis, as well as is in a Phase 2 clinical trial for treatment of moderate-to-severe rosacea. It is also developing DMT410 that has completed Phase Ib POC trials for the treatment of anxillary hyperhidrosis and aesthetic conditions. Dermata Therapeutics, Inc. was incorporated in 2014 and is headquartered in San Diego, California.
Receive News & Ratings for Olaplex Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Olaplex and related companies with MarketBeat.com's FREE daily email newsletter.
